Tenaya Therapeutics, Inc.
TNYA
Positions held
Your positionsTNYA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $122.03M | Enterprise value | $47.89M | Trailing P/E | — | Forward P/E | -1.39 |
| PEG | — | Price / book | 1.76 | Beta | 2.88 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -18.8% |
| Profit margin | 0.0% | ROE | -121.9% | ROA | -47.9% | Debt / equity | 0.06 |
| Current ratio | 4.52 | Free cash flow | -$32.60M | Analyst recommendation | none | Mean target | $3.20 |
| 52w high | $2.35 | 52w low | $0.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $0.2M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -1882.8% | -8917.8% | — | — | — | — |
| Net income | -$43.4M | -$19.3M | -$20.2M | -$20.3M | -$23.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.9M | -$20.1M | -$20.8M | -$20.9M | -$24.1M | — |
- Revenue +393% vs prior quarter ($1.1M vs $0.2M).
- Operating margin expanded to -1882.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$90.6M | -$111M | -$124M | -$124M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$93.3M | -$116M | -$131M | -$126M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-10 · Treasury yields rise as investors raise bets on Fed rate hike: AlphaCheck
2026-09-03 · Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
2026-08-18 · Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
2026-08-05 · Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-04 · Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-15 · Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns